Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | VDR | P11473 | 3/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156788 | 1.00 | ESR1 (0.43) | ESR1ESR2ARVDRNR1H4 | |
| SCHEMBL5158971 | 0.88 | ESR1 (0.39) | ESR1ESR2ARVDRCYP1A1 | |
| SCHEMBL5158963 | 0.88 | ESR1 (0.39) | ESR1ESR2ARVDRCYP1A1 | |
| SCHEMBL13709344 | 0.85 | VDR (0.41) | ESR1ESR2ARVDRNR1H4 | |
| SCHEMBL13709343 | 0.84 | ESR1 (0.37) | ESR1ESR2ARVDRNR1H4 | |
| SCHEMBL13709361 | 0.84 | VDR (0.41) | ESR1ESR2ARVDRCYP1A1 | |
| SCHEMBL12764233 | 0.84 | ESR1 (0.45) | ESR1ESR2ARVDRHDAC6 | |
| SCHEMBL1525452 | 0.83 | RARB (0.41) | ESR1CYP1A1CYP1B1RARB | |
| SCHEMBL1525455 | 0.83 | RARB (0.41) | ESR1CYP1A1CYP1B1RARB | |
| SCHEMBL13709357 | 0.83 | ESR1 (0.36) | ESR1ESR2ARVDRHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | claimed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | claimed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | claimed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | VDR, CYP2R1, CYP24A1 | ESR1 139/4885ESR2 92/4885AR 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.